Rockwell Medical, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; unaudited. Rockwell develops renal drug therapies and manufactures hemodialysis concentrates. The filing was signed May 10, 2016.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Sales | $13.63 million | $13.88 million; down 1.9% |
| Gross profit / margin | $1.69 million / 12.4% | $2.31 million / 16.7% |
| Operating loss | $4.61 million | $3.81 million |
| Net loss | $4.82 million; $0.10 per diluted share | $3.70 million; $0.07 per diluted share |
| Operating cash flow | $(1.07) million | $(3.31) million |
| Cash and cash equivalents | $30.01 million at March 31 | $31.20 million at December 31, 2015 |
| Available-for-sale investments | $39.44 million | $39.48 million at December 31, 2015 |
| Current assets / current liabilities | $85.76 million / $8.01 million | Net working capital: $77.8 million, as stated by management |
| Debt | No long-term debt | No interest expense reported |
Cash and investments totaled approximately $69.4 million. Cash declined by $1.19 million during the quarter. Inventory increased $1.29 million, while deferred license revenue increased $3.47 million. Capital expenditures were $0.20 million.
Material changes and notable items
- Sales fell modestly, but gross profit declined about $0.62 million. Management cited lower contract-manufacturing sales and approximately $0.3 million of value-added taxes associated with the Wanbang license payment.
- SG&A decreased to $4.99 million from $5.33 million, mainly reflecting lower non-cash equity compensation. Research and product development expense increased to $1.31 million from $0.80 million for work on additional indications and regulatory approvals.
- Rockwell received a $4 million upfront payment under its February 2016 Wanbang agreement to license and supply Triferic and Calcitriol in China. The upfront fee is deferred and recognized over the agreement term; further regulatory and revenue milestones could total up to $35 million, with product-sale earnings also possible.
- Most revenue continued to come from dialysis concentrates. Domestic concentrate revenue increased $0.3 million, international concentrate revenue decreased $0.1 million, and third-party contract-manufacturing sales decreased $0.5 million year over year.
Outlook, risks and contingencies
- No formal financial forecast was provided. Management said it expected adequate resources for planned inventory, receivables, and research spending, and anticipated positive operating cash flow as drug sales increase.
- Management expected Triferic sales to remain insignificant until transitional add-on Medicare reimbursement is obtained or the effort to obtain it ends. Approval and timing of that reimbursement were uncertain.
- After quarter-end, FDA approved Triferic Powder Packet on April 25, 2016; management said the format should reduce production and distribution costs. On May 4, Rockwell disclosed a stability issue involving an inactive ingredient in Calcitriol product made by a contract manufacturer. It expected marketing to begin after the issue was resolved, then anticipated in Q3 2016.
- Rockwell was evaluating expansion of concentrate operations in the western U.S. Baxter could fund eligible construction with $5 million at commencement and up to a further $5 million on completion. Baxter’s exclusivity depends on growth targets; termination, loss of exclusivity, or potential repayment of fees are identified risks.
- Key risks include drug commercialization and regulatory execution, reliance on contract manufacturers and suppliers, reimbursement and health-care policy, customer concentration and competition in concentrates, raw-material costs, and the Baxter relationship. Short-duration bond funds were exposed to interest-rate-driven market-value changes; management did not consider them other-than-temporarily impaired. Disclosure controls were judged effective at a reasonable-assurance level, and no material control changes were reported.
Important facts for investors to verify
- Progress and timing of Medicare add-on reimbursement for Triferic, and whether commercial adoption develops.
- Resolution of the Calcitriol stability issue, actual launch timing, and any financial or supply impact.
- Whether the Wanbang agreement produces regulatory approvals, milestone payments, and commercial sales; milestone amounts are contingent.
- Concentrate volumes, margins, and Baxter’s performance against exclusivity targets, including any western U.S. expansion plans.
- Cash burn and working-capital needs as drug inventory, receivables, research spending, and commercialization activity change.